- Home
- GMM vs ICCM Comparison
GMM vs ICCM Comparison
Compare GMM & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GMM | ICCM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 43.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GMM | ICCM |
|---|---|---|
| Price | $1.43 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 40.6K | ★ 382.4K |
| Earning Date | 08-18-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | $0.81 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $0.94 | $0.58 |
| 52 Week High | $4.75 | $1.66 |
Technical Indicators
Market Signals| Indicator | GMM | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 57.06 |
| Support Level | $0.94 | $0.58 |
| Resistance Level | $1.54 | $0.68 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 75.78 | 98.44 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.